QDEL QUIDEL CORP

QuidelOrtho Opens New Distribution Center in Pedricktown, NJ

QuidelOrtho Corporation (Nasdaq: QDEL) has launched a second state-of-the-art United States distribution center in Pedricktown, New Jersey. This strategic endeavor epitomizes QuidelOrtho’s commitment to strengthening supply chain resilience and elevating the customer experience. In collaboration with a third-party logistics provider, this investment in redundancy and capacity is designed to enable QuidelOrtho to fulfill customer orders with agility.

This press release features multimedia. View the full release here:

QuidelOrtho opens second U.S. distribution center (Graphic: Business Wire)

QuidelOrtho opens second U.S. distribution center (Graphic: Business Wire)

“At QuidelOrtho, we embrace a culture of relentless improvement. With the startup of our second distribution center in the United States, we’re making great strides in maintaining and enhancing a truly robust supply chain approach to distribute our products,” said Phil McLellan, Senior Vice President, Operations, QuidelOrtho. “This milestone underscores our dedication to operational excellence and responsiveness to customer feedback.”

QuidelOrtho values sustainable growth and establishing eco-friendly supply chains, also moving to greener packaging for some of its shipments. Its supply chain team has tested a new, paper-based insulation that is fully “curbside” recyclable. While the new packaging will not span across every shipment type, it is expected to positively impact an estimated 15-20% of QuidelOrtho’s domestic shipments, transitioning over the next several months in the United States.

“Building upon our responsible resource management, we are proud of this step toward reducing our environmental footprint,” said Mr. McLellan. “By embracing innovative solutions and fostering a culture of continuous improvement, we’re promoting operational excellence and environmental stewardship.”

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

QuidelOrtho is advancing diagnostics to power a healthier future.

For more information, please visit .

Source: QuidelOrtho Corporation

EN
15/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUIDEL CORP

 PRESS RELEASE

QuidelOrtho® Introduces Results Manager™ System

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. This press release features multimedia. View the full release here: QuidelOrtho® Results Manager™ System (Graphic: Business Wire) The Quid...

 PRESS RELEASE

QuidelOrtho to Participate in the 46th Annual Raymond James Institutio...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrtho’s management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT. Interested parties can access the live webcast and replay in the “Events & Presentations” section ...

 PRESS RELEASE

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Result...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. “We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025,” said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. “The growth of our underlying business with its recurring revenue busin...

 PRESS RELEASE

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter...

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announced 2024 financia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch